---
figid: PMC9469902__fmed-09-961027-g0004
figtitle: 'COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition:
  A novel treatment strategy'
organisms:
- Severe acute respiratory syndrome coronavirus 2
- Coronaviridae
- Severe acute respiratory syndrome-related coronavirus
- unidentified influenza virus
- Middle East respiratory syndrome-related coronavirus
- H1N1 subtype
- H5N1 subtype
- Human coronavirus 229E
- Human coronavirus OC43
- Influenza A virus H3N2
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Sus scrofa
- Sar
pmcid: PMC9469902
filename: fmed-09-961027-g0004.jpg
figlink: /pmc/articles/PMC9469902/figure/F4/
number: F4
caption: IL-6 signaling pathways. IL-6 requires two receptors, the IL-6R and the gp130,
  to begin signaling. IL-6 (classic signaling) binds to either fluid- or membrane-bound
  IL-6R (SIL-6R, trans-signaling). In two modalities of IL-6R signaling, a hexamer
  complex with gp130 is formed. The JAK–MAPK route and the JAK–STAT3 pathway are both
  used by IL-6 to transfer signaling. JAK kinases phosphorylate tyrosine in the cytoplasmic
  region of gp130, which promotes STAT3 phosphorylation and causes homodimerization,
  which works as a transcription factor in the nucleus.
papertitle: 'COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition:
  A novel treatment strategy.'
reftext: Mansoor Khaledi, et al. Front Med (Lausanne). 2022;9:961027.
year: '2022'
doi: 10.3389/fmed.2022.961027
journal_title: Frontiers in Medicine
journal_nlm_ta: Front Med (Lausanne)
publisher_name: Frontiers Media S.A.
keywords: COVID-19 | JAK inhibitors | baricitinib | pacritinib | ruxolitinib | tofacitinib
automl_pathway: 0.9676107
figid_alias: PMC9469902__F4
figtype: Figure
organisms_ner:
- Rattus norvegicus
- Sus scrofa
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC9469902__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9469902__fmed-09-961027-g0004.html
  '@type': Dataset
  description: IL-6 signaling pathways. IL-6 requires two receptors, the IL-6R and
    the gp130, to begin signaling. IL-6 (classic signaling) binds to either fluid-
    or membrane-bound IL-6R (SIL-6R, trans-signaling). In two modalities of IL-6R
    signaling, a hexamer complex with gp130 is formed. The JAK–MAPK route and the
    JAK–STAT3 pathway are both used by IL-6 to transfer signaling. JAK kinases phosphorylate
    tyrosine in the cytoplasmic region of gp130, which promotes STAT3 phosphorylation
    and causes homodimerization, which works as a transcription factor in the nucleus.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Il6r
  - Stat3
  - Il6
  - Socs3
  - Socs1
  - Sos1
  - Sos2
  - Grb2
  - Ptpn11
  - Gab1
  - Pik3cg
  - Akt1
  - IL6R
  - STAT3
  - IL-6
  - SOCS3
  - SOCS1
  - SOS1
  - GRB2
  - GAB1
  - AKT1
  - Il6ra
  - Pik3r1
  - ras
  - Hras
  - Kras
  - Rem1
  - Zhx2
  - Mdk
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - IL6
  - PTPN11
  - PIGU
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT2
  - AKT3
  - KRAS
  - HRAS
  - NRAS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
---
